Every material Form 8-K Jasper Therapeutics, Inc. has filed with the SEC since October 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Jasper Therapeutics announced the results of its offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant, which expired on November 7, 2026. A total of 8,510,658 warrants were properly tendered, about 68.94% of the outstanding warrants, and the company expects to pay $2,757,453.19 in cash for them.
8,510,658 warrants were properly tendered and not withdrawn, about 68.94% of outstanding warrants.
Offer price was $0.324 in cash per warrant, without interest; the offer expired at 12:00 a.m. Eastern Time on November 7, 2026.
The company expects to pay an aggregate of $2,757,453.19 in cash, to be made promptly.
The offer was described in a Schedule TO originally filed with the SEC on October 7, 2026.
Jasper Therapeutics, Nasdaq-listed as JSPR, filed a charter amendment to carry out a 1-for-30 reverse stock split, which takes effect at 12:01 a.m. Eastern Time on November 6, 2026. Each stockholder's percentage ownership is unchanged apart from minor fractional-share adjustments, but the number of shares outstanding falls from about 33.3 million to about 1.1 million.
Ratio of 1-for-30 was set by the board on October 23, 2026, within the 1-for-15 to 1-for-35 range stockholders approved on September 30, 2026.
Shares outstanding fall from about 33.3 million to about 1.1 million; authorized shares stay at 490,000,000.
Cash will be paid in lieu of fractional shares based on the November 5, 2026 closing price.
Trading continues under JSPR on the Nasdaq Capital Market with new CUSIP 471871301.
Jasper Therapeutics said it has completed enrollment of the IgA nephropathy cohort of its Phase 2 basket study of vensobafusp alfa (KP104), with 18 patients enrolled in stage 1. The company expects initial interim data from the IgAN cohort by year-end 2026 and has added an FSGS cohort, with first dosing anticipated in the first quarter of 2027. The filing contains no financial results, so the update is a clinical development milestone rather than a change in reported financial measures.
Enrollment completed in the IgAN cohort: 18 patients across 3 cohorts (Q2W, Q4W and Q8W maintenance, six patients each)
Initial interim data from the IgAN basket study expected by year-end 2026
FSGS expansion cohort added, with first patient anticipated to be dosed in the first quarter of 2027
Jasper Therapeutics, Inc. (Nasdaq: JSPR) commenced an offer to buy any and all of its outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant. The company said the offer aims to reduce the number of shares that could be issued on warrant exercise, which would lessen potential dilution and give shareholders more certainty about the capital structure.
Offer price is $0.324 in cash per warrant, without interest; each warrant exercisable for one share at $2.92.
As of October 6, 2026, 12,345,707 warrants were outstanding; if all are tendered, the company expects to pay about $4.0 million from cash on hand.
The offer expires at one minute after 11:59 p.m. Eastern Time on November 6, 2026, unless extended or terminated, and is not conditioned on a minimum tender.
Warrants not tendered remain outstanding on their original terms and expire at 5:00 p.m. Eastern Time on March 18, 2030.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Jasper Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →